


iRegene Therapeutics
Biotechnology Research • Hongshan District, Hubei, China • 1-10 Employees
Company overview
| Headquarters | 9 Gaokeyuan 3rd Rd, East Lake High-Tech Development Zone, Wuhan, Hubei, CN |
| Phone number | +862765522933 |
| Website | |
| NAICS | 541714 |
| Keywords | Cardiology, Chemicals, Deep Learning, Neurology, Regenerative Medicine, Stem Cell Therapy, Organoids, Chem+Ai, Retinal Degenerative Diseases |
| Founded | 2017 |
| Employees | 1-10 |
| Socials |
Key Contact at iRegene Therapeutics
Emmanuel Montet
Executive Vice President Corporate Development & Strategy
About iRegene Therapeutics
We research and develop proprietary chemically-derived allogeneic cell therapy for degenerative diseases like Parkinson’s Disease, Retinal Degenerative Diseases, Ischemic Stroke, etc. Our leading pipeline NouvNeu001 (Parkinson’s Disease) is scheduled to initiate Phase I clinical trial in 2023 H2. We are a passionate team committed to developing first-in-class therapies for patients suffering from major incurable diseases. Making fast-acting and disease-reversing therapies accessible to patients in the greatest extent possible is our priority.
iRegene Therapeutics revenue & valuation
| Annual revenue | $427,775 |
| Revenue per employee | $86,000 |
| Estimated valuation?This valuation is estimated based on industry average for the Biotechnology Research industry and current estimated revenues | $1,400,000 |
| Total funding | $27,800,000 |
Employees by Management Level
Total employees: 1-10
Seniority
Employees
Funding Data
Explore iRegene Therapeutics's funding history, including investment rounds, total capital raised, and key backers.
iRegene Therapeutics Tech Stack
Discover the technologies and tools that power iRegene Therapeutics's digital infrastructure, from frameworks to analytics platforms.
JavaScript libraries
JavaScript graphics
Programming languages
Web servers
Frequently asked questions
4.8
40,000 users



